ELOX Eloxx Pharmaceuticals Inc

-0.18 (-3.59%)
Sep 25 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 16,300
Bid Price 4.61
Ask Price 5.48
News -
Day High 5.4616


52 Week Range


Day Low 4.71
Company Name Stock Ticker Symbol Market Type
Eloxx Pharmaceuticals Inc ELOX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.18 -3.59% 4.84 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.98 4.71 5.4616 4.84 5.02
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
247 16,300 $ 4.91 $ 80,044 - 1.6959 - 10.90
Last Trade Time Type Quantity Stock Price Currency
17:17:41 3 $ 4.60 USD

Eloxx Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
13.32M 2.75M - 0 -36.07M -13.10 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eloxx Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ELOX Message Board. Create One! See More Posts on ELOX Message Board See More Message Board Posts

Historical ELOX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.995.994.665.2628,400-1.15-19.2%
1 Month4.596.134.545.3936,4820.255.45%
3 Months3.9710.503.55967.781,074,0450.8721.91%
6 Months2.8410.902.23188.22737,8242.0070.42%
1 Year6.79610.901.69597.55445,483-1.96-28.78%
3 Years102.00270.801.695944.68519,374-97.16-95.25%
5 Years642.80700.001.695969.20355,167-637.96-99.25%

Eloxx Pharmaceuticals Description

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis.